Recently, cancer immunotherapy based on the immune microenvironment has developed rapidly, especially the immune checkpoint inhibitor therapy40,41, e.g., CTLA-4, PD-1, etc. Although this therapeutic method has been proven promising, the effects seem very uneven among different patients or different cancer types. The gene discussed is CTLA4; the disease is cancer.